Analyzing Phase 3 ACHIEVE-1 Results for Orforglipron in Type 2 Diabetes from Eli Lilly

Executed on:May 14, 2025 2:30 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: CentraCare HealthBoard Certified Endocrinologist at CentraCare Health 
Manages 400 patients annually for weight loss and obesity.
Practicing in endocrinology for over 20 years with a specific interest in obesity and type 2 diabetes research and treatments

Interview Goal

The goal of the interview is to examine the implications of the recently released Phase 3 results from Eli Lilly’s ACHIEVE-1 trial, evaluating orforglipron—an investigational oral GLP-1 receptor agonist—for adults with type 2 diabetes and inadequate glycemic control. The discussion will delve into the significance of the A1C and weight reduction outcomes, safety and tolerability comparisons with injectable GLP-1s, dosing regimen considerations, and the broader clinical and regulatory implications of introducing a once-daily, small molecule oral GLP-1 therapy to the treatment landscape.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.